BRITAIN has gone fat jab crazy — with sales of Wegovy soaring by more than 2,000 per cent in the past month. Dieters are ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ...

"Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Response Pharmaceuticals公布了其前赛诺菲资产在停用GLP-1药物患者中的二期临床数据，表明该药物能降低患者的血脂水平并抑制体重反弹。 包括礼来（Eli Lilly）的Zepbound和诺和诺德（Novo ...

Eli Lilly's experimental GLP-1 oral pill, orforglipron, showed promise in weight loss, achieving a 12.4% reduction in body weight over 72 weeks in a late-stage study. While below Novo Nordisk's ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.